Clinical Trial Update: Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a telomerase-derived universal cancer peptide vaccine for glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Telomerase-derived universal cancer peptide vaccine (telomerase-derived universal cancer peptides vaccine)

Snippet

Sponsor: Centre Hospitalier Universitaire de Besancon | Conditions: Glioblastoma | Phase 2 | Status: COMPLETED